Skip to content

Study Details

Inhaled Treprostinil: A Study Drug for People with Fibrotic Lung Disease

(IRB#: IRB_00162671)

Idiopathic Pulmonary Fibrosis (IPF) is a rare illness that severally affects the lungs making it hard to breathe. Inhaled Treprostinil is a study drug for people with IPF. The medicine is given by breathing into the lungs using a machine called a nebulizer (breathing device). The machine turns the medicine into a mist to breathe into your lungs. Research is needed to learn the safety and effectiveness of the drug and provide or continue to provide inhaled Treprostinil for people previously in the RIN-PF-301 (TETON) study.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 40 years and older
  • IPF or PPF diagnosis
  • Must have participated in the RIN-PF-301 (TETON) study, remained on the study drug, and completed all scheduled study visits OR was enrolled in the RIN-PF-301 (TETON) study at the time the study OR discontinued by the Sponsor
  • Participants willing and able to use specific birth control
  • Able to attend in person at the University of Utah

Exclusion Criteria

  • Pregnant or breastfeeding
  • Participation causes other health risks
  • Use of any other investigational drug/device or participation in any investigational study

Will I be paid for my time?


For more information contact:

Heather Hammerschmidt


IRB#: IRB_00162671

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2023-06-21 06:00:00

Specialties: Pulmonary

Last Updated: 6/8/23